Brean Murray is reiterating its Buy rating on shares of NPS Pharmaceuticals, Inc. NPSP.
“Although there are no additional presentations directly related to Gattex during the 2011 DDW conference, we draw investor attention to several abstracts related to other GLP-2 analog, such as FE 203799 and ZP1848,” Brean Murray writes.
NPS Pharmaceuticals closed Wednesday at $9.83.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in